Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462525 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02462525 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 74 participants.
The verdict
NCT02462525, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with relapsed and refractory multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG ABBV-838
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-05-06 |
| Est. Completion | 2017-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462525
The ClinicalTrials.gov registry entry for NCT02462525 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02462525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02462525 about?
NCT02462525 is a clinical study titled "Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma". This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with relapsed and refractory multiple myeloma.
What is the current status of trial NCT02462525?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2015-05-06. Estimated completion is 2017-12-06.
What interventions are being tested in trial NCT02462525?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), ABBV-838 (DRUG).
Who is sponsoring clinical trial NCT02462525?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.